An Open-label Bosutinib Treatment Extension Study For Subjects With Chronic Myeloid Leukemia (Cml) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008

Trial Profile

An Open-label Bosutinib Treatment Extension Study For Subjects With Chronic Myeloid Leukemia (Cml) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Bosutinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 30 May 2017 Planned number of patients changed from 287 to 300.
    • 28 Feb 2017 Planned End Date changed from 1 Mar 2020 to 1 Apr 2020.
    • 28 Feb 2017 Planned primary completion date changed from 1 Mar 2020 to 1 Apr 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top